2024年12月11日，广东 东阳光 药业股份有限公司(以下简称“东阳光药”)正式向香港联交所提交了IPO申请，计划以介绍方式在港上市。作为一家成立于2003年的老牌药企，东阳光药曾凭借其核心产品——“ 抗流感 神药”可威(磷酸奥司他韦)，在中国市场上占据绝对优势，一度成为行业内的明星企业。然而，随着市场竞争加剧、政策环境变化以及自身研发管线的局限性，东阳光药的“单品打天下”模式正逐渐失去光芒，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.